This company listing is no longer active
INVV.Y Stock Overview
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Indivior PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£21.85 |
| 52 Week High | UK£75.98 |
| 52 Week Low | UK£14.76 |
| Beta | -0.031 |
| 1 Month Change | -18.79% |
| 3 Month Change | 10.55% |
| 1 Year Change | 28.43% |
| 3 Year Change | 122.46% |
| 5 Year Change | -8.92% |
| Change since IPO | 90.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| INVV.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.5% | 0.9% | 1.2% |
| 1Y | 28.4% | 13.9% | 24.7% |
Return vs Industry: INVV.Y exceeded the US Pharmaceuticals industry which returned 6.4% over the past year.
Return vs Market: INVV.Y exceeded the US Market which returned 14% over the past year.
Price Volatility
| INVV.Y volatility | |
|---|---|
| INVV.Y Average Weekly Movement | 20.2% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INVV.Y's share price has been volatile over the past 3 months.
Volatility Over Time: INVV.Y's weekly volatility has increased from 13% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 1,000 | Mark Crossley | www.indivior.com |
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company’s product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet.
Indivior PLC Fundamentals Summary
| INVV.Y fundamental statistics | |
|---|---|
| Market cap | US$3.01b |
| Earnings (TTM) | -US$50.00m |
| Revenue (TTM) | US$947.00m |
3.2x
P/S Ratio-60.2x
P/E RatioIs INVV.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INVV.Y income statement (TTM) | |
|---|---|
| Revenue | US$947.00m |
| Cost of Revenue | US$161.00m |
| Gross Profit | US$786.00m |
| Other Expenses | US$836.00m |
| Earnings | -US$50.00m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 83.00% |
| Net Profit Margin | -5.28% |
| Debt/Equity Ratio | 331.9% |
How did INVV.Y perform over the long term?
See historical performance and comparison